Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 144 Cr.
- Current Price ₹ 270
- High / Low ₹ 316 / 140
- Stock P/E 22.8
- Book Value ₹ 55.8
- Dividend Yield 0.00 %
- ROCE 35.2 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 134 days to 85.1 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.72%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 17.80 | 61.73 | |
| 15.54 | 52.85 | |
| Operating Profit | 2.26 | 8.88 |
| OPM % | 12.70% | 14.39% |
| 0.03 | 0.08 | |
| Interest | 0.09 | 0.21 |
| Depreciation | 0.01 | 0.02 |
| Profit before tax | 2.19 | 8.73 |
| Tax % | 27.85% | 27.49% |
| 1.59 | 6.33 | |
| EPS in Rs | 3.24 | 12.74 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 247% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 298% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 4.90 | 4.97 |
| Reserves | 13.32 | 22.77 |
| 1.61 | 3.25 | |
| 0.95 | 4.57 | |
| Total Liabilities | 20.78 | 35.56 |
| 0.05 | 1.65 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.42 | 0.43 |
| 20.31 | 33.48 | |
| Total Assets | 20.78 | 35.56 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.87 | 1.14 | |
| -0.52 | -1.56 | |
| 13.13 | 2.92 | |
| Net Cash Flow | 8.74 | 2.50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 66.03 | 86.09 |
| Inventory Days | 103.54 | 42.33 |
| Days Payable | 1.25 | 9.20 |
| Cash Conversion Cycle | 168.32 | 119.22 |
| Working Capital Days | 182.29 | 85.09 |
| ROCE % | 35.18% |
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (LODR), 2015
1d - Board approved Directors' Report FY2024-25; AGM 29 Sep 2025; MOA amended adding cosmetics; section 180 limit subject to shareholder approval
-
Disclosure Under Regulation 30 Of SEBI(LODR)Regulations, 2015
12 Aug - Royal Sense launches 'Stergic Pharmacy' franchise model; 125+ applications received for retail outlets.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 14 Jul
-
Board Meeting Outcome for Disclosure Under Regulation 30 Of The SEBI (Listing
Obligations And Disclosure Requirements) Regulations, 2015
19 Jun - Approved office shift within Delhi; appointed internal and secretarial auditors for FY 2025-26.
-
Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 Of The SEBI (LODR) Regulations 2015, As Amended ('Listing Regulations')
26 May - Royal Sense approves merger with TTG Innovations; share swap ratio 18.1:1; alters shareholding pattern.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.